Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

5-HT1A antagonists with utility in urinary tract disorders under study at Recordati

May 13, 2003

Licensing opportunity from Milkhaus: ML-04 for BPH and prostatitis

May 12, 2003

Cozaar approved for diabetics with kidney disease and high blood pressure in Canada

May 12, 2003

Patients associate clinical improvement with relative, not absolute, reduction in incontinence

May 9, 2003

New potential therapies described for postradical prostatectomy ED

May 9, 2003

New smooth muscle-selective muscarinic antagonists covered by Kyorin patent

May 8, 2003

U.S. approval for Cialis anticipated for second half of 2003

May 7, 2003

New data on the efficacy and safety of vardenafil in erectile dysfunction

May 7, 2003

The effects of Y-27632 in models of erectile dysfunction and overactive bladder

May 6, 2003

Milkhaus completes enrollment in expanded phase II trial with ML-04

May 6, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...